CELYAD ONCOLOGY SA December 1st 2023, Mont-Saint-Guibert, Belgium - Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells announces that its CEO and managing director Georges Rawadi has decided to step down, effective as of Friday December 1, 2023.
Georges has taken this decision for personal reasons. Michel Lussier will take over the CEO responsibilities ad interim. Michel is co-founder and member of the board of Directors of Celyad Oncology.
Hilde Windels, Chair of Celyad Oncology, commented: "We thank Georges for his efforts and dedication to make this pivotal year a success, following Celyad's change in strategy since last year. We wish him every success in the future."
The company's primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments.
Michel Lussier, interim CEO, commented: "We are grateful for the work that Georges has done and I look forward to working closer with the team again in this interim period. I am confident about the company's future: the science is great, we have cash in the bank and we have been very successful in our efforts to address the limitations of CAR-T. Hence, we are ready to engage in value adding partnering discussions."
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Celyad Oncology SA published this content on 01 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2023 21:08:57 UTC.
